Launch of the 4DMedical share price (ASX: 4DX) at 19% on the first commercial scans



Image source: Getty Images

The 4DMedical Ltée (ASX: 4DX) The share price is up today following the rollout of the company’s respiratory imaging platform.

As of this writing, 4DMedical shares are trading for $ 1.43, up 19.17%.

4DMedical is making great strides on XV LVAS

In today’s statement, 4DMedical announced that it has partnered with the I-MED Radiology Network (I-MED) for the commercial deployment of its XV Pulmonary Ventilation Analysis Software (XV LVAS) .

I-MED is Australia’s largest supplier of diagnostic imaging with over 250 clinics across the country.

The first XV LVAS deployment will take place next month at the Berwick Clinic in Melbourne after a successful pilot program. Clinicians and specialists based in and around the Casey area of ​​Victoria, Australia will soon be able to refer patients to I-MED’s state-of-the-art Berwick Imaging Clinic.

4DMedical’s proprietary XV LVAS technology converts X-ray images into a four-dimensional data set using models and mathematical algorithms. The platform then provides physicians with information about a patient’s lung movements and airflow. This allows for the detection and monitoring of various lung diseases which can be managed or treated if possible.

XV LVAS is expected to be further installed in hospitals and imaging centers, providing greater accessibility for all patients. This includes sites in Brisbane and Wagga Wagga in early 2022 and at selected locations on the I-MED network thereafter.

In addition, all establishments with XV LVAS will be able to offer the 4DMedical pulmonary report for inpatient and outpatient care. This in turn should maximize the number of addressable patients for the business, thereby increasing revenue streams.

4DMedical is making progress with its commercial pilots in the United States. The company currently has a short-term commercialization pipeline, particularly within the large and large healthcare system of the Veterans Health Administration (VHA).

The respiratory diagnostics industry is worth an estimated US $ 31 billion per year worldwide. The United States, the world’s largest healthcare market, represents an annual opportunity of US $ 13.7 billion.

About the 4DMedical share price

Despite today’s gain, 4DMedical shares disappointed investors as the company’s stock price fell 40% in the past 12 months. The company’s stock price hit a 6-month low at $ 1.16 yesterday before rebounding higher.

4DMedical has a market capitalization of approximately $ 292 million, with over 208.95 million shares outstanding.



Comments are closed.